Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Brian Culley Purchases 40,500 Shares of Company Stock

Lineage Cell Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Brian Culley bought 40,500 shares at an average price of $0.92, spending $37,260 and increasing his direct stake by 15.85% to 296,016 shares.
  • Lineage reported quarterly EPS of -$0.03, matching expectations, while revenue of $1.43 million fell short of the $2.32 million consensus estimate.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $6.25; shares opened at $0.80 and have traded between $0.77 and $1.99 over the past year.
  • Five stocks we like better than Lineage Cell Therapeutics.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian Culley bought 40,500 shares of Lineage Cell Therapeutics stock in a transaction on Monday, November 16th. The shares were purchased at an average cost of $0.92 per share, with a total value of $37,260.00. Following the acquisition, the chief executive officer directly owned 296,016 shares of the company's stock, valued at approximately $272,334.72. The trade was a 15.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN:LCTX opened at $0.80 on Tuesday. The business's 50 day moving average price is $0.99 and its 200-day moving average price is $1.29. The firm has a market capitalization of $202.33 million, a PE ratio of -8.89 and a beta of 1.68. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $1.99.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The firm had revenue of $1.43 million during the quarter, compared to the consensus estimate of $2.32 million. Lineage Cell Therapeutics had a return on equity of 3.37% and a net margin of 16.18%. As a group, analysts expect that Lineage Cell Therapeutics, Inc. will post -0.07 earnings per share for the current year.

Analyst Ratings Changes

Separately, Raymond James Financial reissued a "market perform" rating on shares of Lineage Cell Therapeutics in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Read Our Latest Stock Analysis on LCTX

Institutional Trading of Lineage Cell Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LCTX. StoneX Group Inc. grew its position in Lineage Cell Therapeutics by 74.9% in the third quarter. StoneX Group Inc. now owns 29,747 shares of the company's stock worth $30,000 after acquiring an additional 12,739 shares during the period. Equitable Holdings Inc. purchased a new position in shares of Lineage Cell Therapeutics during the 2nd quarter worth $39,000. Two Sigma Securities LLC grew its holdings in shares of Lineage Cell Therapeutics by 85.4% during the 2nd quarter. Two Sigma Securities LLC now owns 37,793 shares of the company's stock worth $50,000 after purchasing an additional 17,403 shares during the period. State of Wyoming acquired a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $57,000. Finally, Cibc World Market Inc. acquired a new stake in shares of Lineage Cell Therapeutics during the 2nd quarter worth about $62,000. Institutional investors and hedge funds own 62.47% of the company's stock.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lineage Cell Therapeutics Right Now?

Before you consider Lineage Cell Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.

While Lineage Cell Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines